Related Experiment Videos
Endothelin in organ transplantation
1Department of Medicine III, University of Vienna, Austria.
Summary
Endothelin (ET) is upregulated in rejecting organ transplants and may drive complications like hypertension and allograft dysfunction. Targeting ET receptors could prevent or treat these serious post-transplant issues.
Area of Science:
- Immunology
- Transplantation Medicine
- Vascular Biology
Background:
- Solid organ allografts face complications from ischemia, rejection, and vasculopathy.
- Endothelin (ET) production is increased in rejecting allografts by endothelial cells and infiltrating immune cells.
- ET's vasoconstrictive and mitogenic properties suggest a role in transplant dysfunction.
Purpose of the Study:
- To investigate the role of endothelin (ET) in post-transplantation complications.
- To explore the potential of ET receptor antagonists as a therapeutic strategy.
Main Methods:
- In vivo and in vitro studies examining ET production in rejecting allografts.
- Analysis of plasma ET levels and effects of immunosuppressive drugs.
- Evaluation of ET's vasoconstrictive and mitogenic effects.
Main Results:
- Local upregulation of ET production observed in rejecting allografts.
- ET is produced by both endothelial cells and graft-infiltrating mononuclear cells.
- Elevated plasma ET levels correlate with rejection episodes.
Conclusions:
- Endothelin (ET) may initiate and propagate post-transplantation complications, including hypertension and allograft dysfunction.
- ET receptor antagonists represent a rational therapeutic approach to manage or prevent these complications.